Conferences
ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
16th International Myeloma Workshop
1 - 4 Mar 2017
Novotel and Pullman Hotel, New Delhi, India
IMW 2017 highlights
Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France
7 Mar 2017
Outcome of third salvage autologous stem cell transplantation in multiple myelom...
Dr Laurent Garderet - Hôpital Saint Antoine, Paris, France
7 Mar 2017
Treatment of multiple myeloma patients in the relapsed setting: Expert discussio...
Prof Maria-Victoria Mateos, Prof Paul Richardson
5 Mar 2017
Multiple myeloma highlights from IMW 2017
Prof Phillipe Moreau, Prof Philip McCarthy, Prof Jens Hillengass, Prof Meletios ...
4 Mar 2017
Evaluating efficacy of denosumab compared with zoledronic acid in symptomatic my...
Dr Noopar Raje - Massachusetts General Hospital, Boston, USA
4 Mar 2017
Long term effects of myeloma treatment
Monica Morris - Myeloma UK, Edinburgh, UK
3 Mar 2017
Update on CASTOR trial: Daratumumab, bortezomib, and dexamethasone for relapsed ...
Dr Suzanne Lentzsch - Columbia University, New York, USA
3 Mar 2017
Caring for multiple myeloma carers
Monica Morris - Myeloma UK, Edinburgh, UK
3 Mar 2017
Impact of recurrent myeloma alterations on drug response
Dr Muntasir Mamun Majumder - University of Helsinki, Helsinki, Finland
3 Mar 2017
What is the biology behind immunotherapy for MM?
Dr Alexander Lesokhin - Memorial Sloan Kettering Cancer Center, New York, USA
3 Mar 2017
Evolving role of MRD negativity in multiple myeloma
Prof Jesús San Miguel - University Hospital, Salamanca, Spain
3 Mar 2017
Role of immunotherapy and precision medicines in multiple myeloma and key new gu...
Prof Sagar Lonial - Emory University, Atlanta, USA
3 Mar 2017
Carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple mye...
Dr Ralph Boccia - Center for Cancer and Blood Disorders, Bethesda, USA
3 Mar 2017
Is precision myeloma medicine more hype than reality?
Dr Suzanne Lentzsch - Columbia University, New York, USA
3 Mar 2017
Asia-Pacific approaches to myeloma trials
Prof Chng Wee Joo - National University Health System, Singapore, Singapore
3 Mar 2017
Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myelom...
Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece
3 Mar 2017
Bone disease and management of myeloma complications
Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece
3 Mar 2017
Monoclonal antibodies in multiple myeloma
Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain
2 Mar 2017
Treatment options for newly diagnosed multiple myeloma and management of bone di...
Prof Sonneveld, Prof Cavo, Prof Terpos and Professor Voorhees
2 Mar 2017
Promising myeloma agents in phase II trials
Dr Ruben Niesvizky - New York Presbyterian Hospital-Weill Cornell Medical Center...
2 Mar 2017
Ongoing transplant phase III trials for myeloma
Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA
2 Mar 2017
Post autologous transplant therapies in high risk multiple myeloma: StaMINA tria...
Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA
2 Mar 2017
Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib f...
Dr David Siegel - John Theurer Cancer Center, Hackensack, USA
2 Mar 2017
Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myel...
Dr David Siegel - John Theurer Cancer Center, Hackensack, USA
2 Mar 2017
How should we treat smoldering multiple myeloma? Expert discussion from IMW 2017
Prof Maria-Victoria Mateos, Prof Paul Richardson
2 Mar 2017
Examining strategies to tailor multiple myeloma immunotherapy
Dr Jeffrey Zonder - Karmanos Cancer Institute, Detroit, USA
2 Mar 2017
Sequencing multiple myeloma using blood tests
Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA
2 Mar 2017
